UNITED ~~STATES SECURITIES~~ ~~AND EXCHANGE COMMISSION Washington, D.C. 20549~~STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~August 3022, 2008

SCIELE PHARMA, INC.

(Exact name of registrant as specified in ~~its~~ charter)

Delaware	000-30123	58-2004779
(State of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Five Concourse Parkway

Suite 1800 ~~Atlanta, Georgia 30328~~

Atlanta, Georgia 30328

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (770) 442-9707

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act o Soliciting material pursuant to Rule 14a-12 under the Exchange Act o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

~~Item~~o Soliciting ~~2.02~~material ~~Results~~pursuant ofto ~~Operations~~Rule 14a-12 under ~~and~~the ~~Financial~~Exchange ~~Condition~~Act

~~On April 30,~~o Pre-commencement ~~2008,~~communications ~~Sciele~~pursuant ~~Pharma, Inc.~~to ~~issued a press release announcing its results for the fiscal quarter ended March~~Rule ~~31, 2008. A copy of~~14d-2(b) under the ~~press~~Exchange ~~release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.~~Act

~~In accordance with General Instruction B.2 of Form 8~~o Pre-K,commencement ~~the~~communications ~~information~~pursuant ~~in this~~to ~~Current Report on Form~~Rule 813e-~~K, including Exhibit~~4(c) ~~99.1, shall not be~~under ~~deemed “filed” for~~ the ~~purposes of Section 18 of the Securities~~ Exchange ~~Act~~ ~~of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities~~ Act ~~of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.~~

Item 91.01 ~~Financial~~Entry ~~Statements~~into ~~and~~a ~~Exhibits~~Material Agreement

On July 7, 2008, Sciele Pharma, Inc. (dthe “Company”) ~~Exhibits~~ appointed Mr. Joseph Ciaffoni as its Executive Vice President, Chief Commercial Officer. Mr. Ciaffoni’s appointment was approved by the Company’s Board of Directors on August 22, 2008. Mr. Ciaffoni’s employment agreement dated July 7, 2008 is attached to this report as exhibit 9.01.

~~Exhibit 99.1 Press~~Item ~~release issued by Sciele Pharma, Inc~~9.01 ~~on April 30, 2008.~~Exhibits

29.01 Employment Agreement between the Company and Joseph Ciaffoni dated July 7, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Sciele Pharma, Inc.
		SCIELE PHARMA, INC.
	~~(Registrant)~~	(Registrant)
	By:	/s/ Darrell Borne
		Darrell Borne
	Name:	Darrell Borne
		Executive Vice President, Chief Financial
	Title:	EVP, Chief Financial Officer, Secretary and
		Officer, Secretary and Treasurer
		Treasurer
Date: April 30, 2008
Date: August 27, 2008

Exhibits

Exhibit No.		Description
99.1		Press release issued by Sciele Pharma, Inc. on April 30, 2008.

Filing Compare · SCIELE PHARMA, INC.